Clinical Research Directory
Browse clinical research sites, groups, and studies.
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Sponsor: Western Institute for Veterans Research
Summary
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
Official title: Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-03-25
Completion Date
2026-12
Last Updated
2024-04-05
Healthy Volunteers
No
Conditions
Interventions
Human Papillomavirus 9-valent Vaccine, Recombinant
0.5-mL suspension of 9-valent Gardasil administered as intramuscular injection at weeks 0, 4, and 20
Normal Saline
0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
Locations (2)
University of Utah Midvalley Health Center
Salt Lake City, Utah, United States
VA Salt Lake City Health Care System
Salt Lake City, Utah, United States